Latest News about Psychedelic/Assisted Therapies
Recent news which mentions Psychedelic/Assisted Therapies
Tickers 
   NEWS
  
  Tags
   Psychedelic/Assisted Therapies
   Luisa Gambier de Álvarez de Toledo
   Argentine Psychoanalytic Association
  
  From Benzinga
 From Benzinga
 
   How Strategic Real Estate Investments Are Driving Psychedelic Therapy's Growth, Bridging Gaps In Mental Healthcare
   
  
  
  June 24, 2024
  From Benzinga
 
   Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
   
  
  
  April 17, 2024
  From Benzinga
 
   Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
   
  
  
  April 15, 2024
  From Benzinga
 From Benzinga
 
   Psychedelics Reform Update: Missouri's $10M Budget, Maine's & Maryland's Study Groups, Oregon's Re-Crim And More
   
  
  April 05, 2024
  From Benzinga
 From Benzinga
 
   Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
   
  
  
  March 29, 2024
  From Benzinga
 From Benzinga
 
   Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
   
  
  
  March 27, 2024
  From Benzinga
 
   Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
   
  
  
  March 20, 2024
  From Benzinga
 
   Psychedelics Update: Task Forces In Three States, Decrim No-Go, Arizona Psilocybin Centers, Utah And More
   
  
  March 18, 2024
  From Benzinga
 
   Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
   
  
  
  March 16, 2024
  From Benzinga
 
   Fed Agency Grants $14M To Gilgamesh For Cardiac-Safe Ibogaine Analog Targeting Opioid Use Disorder
   
  March 15, 2024
  Tickers 
   NEWS
  
  
  From Benzinga
 From Benzinga
 
   Psyence Biomedical Will Undertake Psilocybin Clinical Trials For Palliative Care In Australia
   
  March 11, 2024
  Tickers 
   PBM
  
  
  From Benzinga
 
   MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
   
  
  
  March 08, 2024
  From Benzinga
 From Benzinga
 
   Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More
   
  
  
  March 06, 2024
  From Benzinga
 
   Psychedelics Reform Update: Connecticut's Decriminalization, Vermont Hearings, Arizona's Psilocybin Services & More
   
  
  March 01, 2024
  From Benzinga
 
   Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
   
  
  
  March 01, 2024
  From Benzinga
 
   GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
   
  
  
  February 29, 2024
  From Benzinga
 
   Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
   
  February 29, 2024
  Tickers 
   CMPS
  
  
  From Benzinga
 
   Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
   
  
  
  February 29, 2024
  From Benzinga
 
   Beckley Academy's Open-Source Psychedelic Therapy Learning Framework Is Out: What's It All About? Authoring Team Shares Insights
   
  
  February 29, 2024
  From Benzinga
 
   MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
   
  February 28, 2024
  Tickers 
   MNMD
  
  
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.